NCT07016165View on ClinicalTrials.gov

Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies

PHASE4RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Neutropenic FeverAcute Lymphoblastic LeukemiaAcute Myeloblastic LeukemiaNon Hodgkin Lymphoma

Interventions

DRUG

Ceftazidime

Ceftazidime 150 mg/kgBW/24 hours divided into 3 doses.

DRUG

Ciprofloxacin

Ciprofloxacin 10 mg/kgBW/12 hours

Trial Locations (1)

Unknown

RECRUITING

RSUP dr Sardjito, Sleman

All Listed Sponsors

lead

Gadjah Mada University

OTHER

NCT07016165 - Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies | Biotech Hunter | Biotech Hunter